Practice

Contributor: No Good Deed Goes Unpunished—How PBM Mandates Increase Practice Variability

May 17th 2022

By Jeff Patton, MD

Jeff Patton, MD, CEO and board member at OneOncology, dived into the controversial role that pharmacy benefit managers (PBMs) play in formulary decision-making and how PBMs impact biosimilar utilization.

Alvotech Announces Positive Phase 1 Results for Ustekinumab Biosimilar

May 16th 2022

By Skylar Jeremias

Article

In a pharmacokinetic study, Alvotech’s ustekinumab biosimilar referencing Stelara was shown to have comparable safety and efficacy to the reference product, according to the company’s preliminary results.

Conference Posters Highlight Real-world Trends of Biosimilars, Reclassified Biologics

May 14th 2022

By Skylar Jeremias

Article

Posters from the Academy of Managed Care Pharmacy (AMCP)’s annual meeting examined the real-world patterns of biosimilar utilization and the impact of products that have been reclassified as biologics on Medicaid spending.

Health IT for Biosimilars Spotlight: Cardinal Health's Decision Pathway

May 10th 2022

By Skylar Jeremias

Video

Amy Valley, vice president of clinical strategy and technology solutions at Cardinal Health, details the company's Decision Pathway, a health information technology (IT) tool that can assist practices with prescribing patients the lowest-cost product, including biosimilars.

Given Public Concerns, Canadian Policy Makers Should Be Cautious When Making New Biosimilar Policies

May 5th 2022

By Skylar Jeremias

Article

A report on biosimilar uptake and existing policies signals that policy makers should proceed with caution when establishing new policies to boost biosimilar utilization and savings, as many patients and providers still have concerns on their usage.

Opinion: Efforts to Improve Biosimilars Education Are a Start, but Payer Policies Must Catch Up

May 2nd 2022

By Mike Gladstone

Article

Despite improvements in biosimilar education efforts for future health care professionals, payer policies need a major revamp to ensure that biosimilar use is encouraged, according to Pfizer's Mike Gladstone.

Opinion: Biosimilar Adoption Will Help Achieve a Bipartisan Goal

April 25th 2022

By Robert Popovian, PharmD, MS

Article

Biosimilars provide significant savings and encourages competition in the biopharmaceutical marketplace but the United States needs to do more to empower uptake and address adoption barriers, according to Robert Popovian PharmD, MS.

Pegfilgrastim Biosimilars Provide Clinical, Economic Benefits to Prevent Febrile Neutropenia

April 18th 2022

By Laura Joszt

Article

An analysis of real-world dosing and effectiveness of pegfilgrastim biosimilars found the clinical benefits of preventing febrile neutropenia in patients with intermediate to high risk come at acceptable financial costs compared with filgrastim biosimilars.

Dr Edward Arrowsmith Discusses Clinical Pathways, Biosimilars in Ensuring Quality of Care

April 5th 2022

By Skylar Jeremias

Video

Edward Arrowsmith, MD, discussed his recent paper on the use of clinical pathways for specific cancer types and how biosimilar development can help ensure quality of care for patients with limited therapeutic options.

Dr Chelsee Jensen and Dr Eric Tichy Discuss the Mayo Clinic's Success With Biosimilar Adoption

April 3rd 2022

By Skylar Jeremias

Video

Chelsee Jensen, PharmD, and Eric Tichy, PharmD, MBA, who coauthored a paper on the Mayo Clinic's success with implementing biosimilars, discuss their study and how their practice is expected to evolve to improve its approach.